CytoDyn Inc (PK:CYDY)

Business Focus: Bio Therapeutic Drugs

Get the company report for the most recent outlook updated daily

May 28, 2024 08:30 am ET

CytoDyn to Host Webcast to Provide Company Update

CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Dr. Jacob P. Lalezari, Chief Executive Officer,...

May 16, 2024 08:30 am ET

May 2024 Letter to Shareholders

Dear Shareholders, I write today to provide an update on CytoDyn Inc. (“CytoDyn” or “Company”), as we approach the end of our 2024 fiscal year (May 31, 2024), and to sincerely thank you for your unwavering support. Fiscal year 2024 was a...

Feb 29, 2024 08:30 am ET

CytoDyn Announces FDA Has Lifted Clinical Hold

Feb 01, 2024 08:30 am ET

CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma

Jan 29, 2024 08:30 am ET

CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO

Jan 18, 2024 10:11 am ET

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of CytoDyn Inc. (OTC: CYDY)

NEW YORK, Jan. 18, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating CytoDyn Inc. (OTC: CYDY) on behalf of the company's shareholders. The investigation seeks to determine whether CytoDyn's directors breached their fiduciary duties in connection with recent corporate actions.

Dec 07, 2023 04:00 pm ET

CytoDyn Announces Webcast to Provide Company Update

Nov 21, 2023 08:30 am ET

CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO

CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the appointment of Dr. Jacob Lalezari as interim CEO,...

Nov 03, 2023 04:02 pm ET

November 2023 Letter to Shareholders

Dear Shareholders, We write to provide an update on CytoDyn Inc. (“CytoDyn” or “Company”), and to thank you for your continued support of the Company. Throughout our history, CytoDyn has made great strides in developing leronlimab from a single...

Jul 11, 2023 04:05 pm ET

CytoDyn Announces Company Updates and Investment Community Update Webcast

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a clinical-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that it has filed a supplemental...

May 24, 2023 05:05 pm ET

CytoDyn Announces President Takes Medical Leave of Absence

Apr 05, 2023 08:30 am ET

CytoDyn to Hold Webcast to Provide a Company Update

Dec 23, 2022 08:00 am ET

CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO

CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, will hold a webcast on December 29, 2022 at 8:00 a.m. Pacific Time...

Nov 22, 2022 08:30 am ET

CytoDyn to Host R&D Update on Wednesday, December 7, 2022

Oct 28, 2022 05:15 pm ET

CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues

CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that it has voluntarily withdrawn its pending...

Oct 20, 2022 08:30 am ET

CytoDyn Announces Appointment of Additional Directors with Industry Experience

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced additional changes in its Board of Directors (the...

Sep 19, 2022 08:30 am ET

CytoDyn to Hold Webcast to Provide a Quarterly Company Update

Aug 24, 2022 05:10 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CytoDyn Inc. - CYDY

Pomerantz LLP is investigating claims on behalf of investors of CytoDyn Inc. (“CytoDyn” or the “Company”) (OTCMKTS: CYDY). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...

Aug 15, 2022 09:00 pm ET

Bragar Eagel & Squire, P.C. Is Investigating CytoDyn, the WWE, F45, and Hyzon Motors and Encourages Investors to Contact the Firm

, August 15, 2022 – Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against CytoDyn, Inc. (OTCMKTS: CYDY), World Wrestling Entertainment, Inc. (NYSE: WWE), F45 Training Holdings,...

Aug 11, 2022 09:00 pm ET

CYTODYN ALERT: Bragar Eagel & Squire, P.C. is Investigating CytoDyn, Inc. on Behalf of CytoDyn Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against CytoDyn, Inc. (“CytoDyn” or the “Company”) (OTCMKTS: CYDY) on behalf of CytoDyn stockholders. Our investigation concerns whether CytoDyn has violated the federal securities laws and/or engaged in other unlawful business practices.

Aug 10, 2022 09:00 pm ET

CYTODYN ALERT: Bragar Eagel & Squire, P.C. is Investigating CytoDyn, Inc. on Behalf of CytoDyn Stockholders and Encourages Investors to Contact the Firm

Aug 09, 2022 02:26 am ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CytoDyn Inc. - CYDY

NEW YORK, Aug. 9, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of CytoDyn Inc. ("CytoDyn" or the "Company") (OTCMKTS: CYDY). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Jul 13, 2022 08:30 am ET

CytoDyn Appoints Cyrus Arman, Ph.D., MBA, as President

CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the appointment of Dr. Cyrus Arman as President...

Jul 11, 2022 08:30 am ET

CytoDyn Highlights NIH Grant for HIV Functional Cure Preclinical Study of Gene Therapy Based on Leronlimab

Jun 22, 2022 08:30 am ET

CytoDyn to Hold Webcast to Provide a Quarterly Company Update

May 23, 2022 08:30 am ET

CytoDyn Announces Resolution of Legal Dispute with Former Chief Medical Officer

CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that it has reached a non-cash settlement with its...

May 13, 2022 08:00 am ET

CytoDyn Announces the Addition of Leading Experts in Oncology, Infectious Diseases, and Neuroinflammation to its Scientific Board of Advisors; Dr. Jay Lalezari to Serve as Outside Scientific Advisor

CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the addition of Dr. Paul Edison, Dr. Kabir Mody, and...

Apr 12, 2022 08:30 am ET

CytoDyn Announces Publication of Peer-Reviewed Paper, “Suppression of Human and Simian Immunodeficiency Virus Replication with the CCR5-Specific Antibody Leronlimab in Two Species”

Mar 30, 2022 05:00 pm ET

CytoDyn Announces Partial Clinical Hold of HIV Program and Full Clinical Hold of COVID-19 Program

Mar 30, 2022 08:30 am ET

CytoDyn to Hold Webcast to Provide Company Update

Mar 18, 2022 09:29 pm ET

CYTODYN TECHNOLOGIES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of CytoDyn Inc. - CYDY

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into CytoDyn Inc. (OTC: CYDY).

Jan 25, 2022 06:06 pm ET

CytoDyn Announces Leadership Transition Plan to Support Regulatory Approval and Commercialization of Leronlimab

Today the Board of Directors (“the Board”) of CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced a leadership transition plan. Effective immediately, Antonio Migliarese, currently CytoDyn’s Chief Financial Officer, has been appointed interim President. The Board of Directors terminated the employment of Nader Z. Pourhassan, Ph.D., as President and CEO of the Company and he is no longer a member of the Board of Directors, effective January 24, 2022. The rest

Jan 13, 2022 09:00 am ET

CytoDyn Cancels Webcast and Live Q/A Scheduled for Today

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced it has canceled its webcast scheduled for today, Thursday, January 13, 2022 and will provide an update at a future date.

Jan 11, 2022 04:35 pm ET

CytoDyn to Hold Webcast and Live Q/A on January 13

Jan 10, 2022 08:00 am ET

Published Paper Indicates Leronlimab Shows Activity Against 4-Class Drug Resistant HIV-1 From Heavily Treatment Experienced (“HTE") Subjects

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that a research paper entitled “Leronlimab (PRO 140) activity against 4-class drug resistant HIV-1 from Heavily Treatment Experienced Subjects” has been accepted, peer reviewed and is available as a journal pre-proof on ScienceDirect. ScienceDirect provides access to a large bibliographic database of scientific and medical publications of the Dutch publisher Elsevier. This article is availab

Jan 10, 2022 08:00 am ET

Regnum Signs Assignment and Assumption Agreement with CytoDyn and SevenScore Pharmaceuticals to Commercialize Leronlimab in the U.S. for the Treatment of HIV

NEW YORK, Jan. 10, 2022 /PRNewswire/ -- Regnum Corp. (OTCMKT: RGMP) ("Regnum"), CytoDyn Inc. (OTC.QB: CYDY) ("CytoDyn"), and SevenScore Pharmaceuticals, LLC ("SevenScore"), today announced the assignment of the Commercialization and License Agreement ("CLA") and a related Supply Agreement to commercialize leronlimab (PRO 140) in the U.S. for the treatment of HIV from SevenScore to Regnum. The CLA was signed between Vyera Pharmaceuticals, LLC ("Vyera") and CytoDyn on December 17, 2019 and assigned to SevenScore on October 29, 2020.

Jan 05, 2022 09:26 am ET

Leronlimab 14-Week, NASH Clinical Trial Met Primary Endpoint (PDFF) and Secondary Endpoint (cT1) for Per Protocol Population in 350 mg Weekly Dose

CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced positive results from the 350 mg weekly dose of its Phase 2 NASH clinical trial. The trial was conducted in two parts. Part 1 compared a 700 mg weekly dose and placebo in a double-blind randomized manner and Part 2 evaluated a 350 mg weekly dose as an open label study compared to the same placebo blinded arm. Results of the topline report will be announced when available.

Dec 22, 2021 08:39 am ET

CytoDyn Announces Favorable Ruling Granting Injunction Against Former CRO

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that the U.S. District Court for the District of Maryland has granted CytoDyn’s previously-announced motion for a preliminary injunction against NSF International, Inc. and its subsidiary Amarex Clinical Research (“Amarex”), the Company’s former Contract Research Organization (“CRO”).

Dec 21, 2021 08:56 am ET

CytoDyn Receives Positive Response From FDA in Regard to its Phase 3, Registrational Trial in COVID-19 Critically Ill Population

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that it has received a positive response from the U.S. Food and Drug Administration (“FDA”) to conduct a Phase 3, randomized, double blind, placebo controlled trial to evaluate the efficacy and safety of leronlimab in combination with standard of care for critically ill patients with COVID-19 pneumonia with need for Invasive Mechanical Ventilation ("IMV”) or Extracorporeal Membrane Oxygenati

Dec 13, 2021 08:00 am ET

NASH Phase 2 Trial Open-Label Portion Demonstrates Average 80 msec cT1 Reduction in 50% of Patients and Reduction of Nearly 50 msec in 80% of Patients

CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today additional preliminary results to date from the 20 patients who have completed the open-label portion of the Phase 2 trial for NASH (Nonalcoholic steatohepatitis).

Dec 10, 2021 03:59 pm ET

CytoDyn to Hold Webcast and Live Q/A on December 14

Dec 09, 2021 08:56 am ET

CytoDyn Submits Protocol with the FDA for Phase 3 Registrational Trial of Leronlimab for Critically Ill COVID-19 Population

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that it has submitted a Phase 3, randomized, double blind, placebo controlled trial with the U.S. Food and Drug Administration (“FDA”) to evaluate the efficacy and safety of leronlimab in combination with standard of care for critically ill patients with COVID-19 pneumonia with need for invasive mechanical ventilation ("IMV”) or Extracorporeal Membrane Oxygenation (“ECMO”).

Dec 09, 2021 08:26 am ET

CytoDyn Files for Expanded Access Use of Leronlimab for Multi-Drug Resistance HIV Patients

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today filed a request with the U.S. Food and Drug Administration (“FDA”) for approval of expanded access use of leronlimab for multi-drug resistance (MDR) HIV patients. The Company has also previously sought FDA approval for CytoDyn to charge for leronlimab used in this patient population and is preparing to file the last portion of this request.

Dec 08, 2021 08:44 am ET

CytoDyn’s CRO in Brazil Met with ANVISA to Modify CD16 Trial for Critically Ill COVID-19 Patients to Expedite Interim Analysis After 51 Patients, Potentially in 1Q2022

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that its CRO in Brazil (Academic Research Organization (ARO) Albert Einstein Israelite Hospital (AEIH)) met with the Brazilian Health Regulatory Agency (ANVISA) and received its agreement to modify the CD16 trial for critically ill COVID-19 patients. ANVISA has authorized CytoDyn to submit the requested changes. CytoDyn will submit the revised protocol for CD16 providing for a reduction in t

Dec 01, 2021 08:00 am ET

CytoDyn Submits CMC (Manufacturing) Section of HIV BLA to FDA Under Previously Authorized Rolling Review; Last (Clinical) Section Will Complete Full BLA Submission

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced it has completed submission of all the major sections of CMC modules to FDA, some remaining supporting documentation will be submitted under Regional Information before the end of this week. CMC is a critical part of CytoDyn’s Biologics License Application (“BLA”) for HIV. This submission was made under rolling review consistent with guidance from the U.S. Food and Drug Administration (“FDA”

Nov 29, 2021 04:27 pm ET

CytoDyn’s Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at World Antiviral Congress 2021 Beginning Tomorrow

CytoDyn Inc. (OTCQB:CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, reminded investors that Dr. Scott Kelly, CytoDyn’s Chairman of the Board, Chief Medical Officer and Head of Business Development, will present at the World Antiviral Congress being held tomorrow, November 30, 2021 through Thursday, December 2, 2021.

Nov 24, 2021 04:01 pm ET

CytoDyn Announces Preliminary Results from 2021 Annual Meeting

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced the preliminary vote results from the 2021 Annual Meeting of Stockholders (the “Annual Meeting”), which was held today.

Nov 24, 2021 08:55 am ET

Leronlimab (350 mg) Weekly Use for 14 Weeks in Open Label Arm of NASH Trial Produces Fibrosis Reduction as High as 93 msec Amongst First 15 Patients with Average Reduction of 24 msec

Nov 19, 2021 08:00 am ET

CytoDyn Research Paper on Leronlimab Published in Frontiers in Immunology Journal

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that its research paper entitled “CCR5 receptor occupancy analysis reveals increased peripheral blood CCR5+CD4+ T cells following treatment with the anti-CCR5 antibody Leronlimab” has been accepted by Frontiers in Immunology, a leading journal in its field publishing rigorously peer-reviewed research across basic, translational and clinical immunology.

Nov 16, 2021 04:00 pm ET

Health Canada Authorizes Emergency Use of Leronlimab for Treatment of First Triple-Negative Breast Cancer Patient in Canada

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that Health Canada authorized the emergency use of leronlimab for the treatment of a patient with metastatic triple-negative breast cancer (mTNBC).

Nov 16, 2021 02:00 pm ET

CytoDyn Reminds Stockholders to Register 24 hours before November 24th Annual Meeting

Nov 16, 2021 06:00 am ET

CytoDyn Submits the First of Three Main Sections of HIV BLA to FDA Under Previously Authorized Rolling Review

Nov 08, 2021 06:00 am ET

CytoDyn Submits Breakthrough Therapy Designation Application to FDA for Leronlimab as a Treatment for Metastatic Triple-Negative Breast Cancer (mTNBC); Fast Track Designation for mTNBC was received pr

Nov 03, 2021 06:00 am ET

CytoDyn Announces Cancer Update: 12-month Analysis of 28 mTNBC Patients Receiving Leronlimab Suggests an Increase of 3600% in 12-month OS in 75% of Patients with a Lower Level of Circulating Cells Aft

Nov 03, 2021 06:00 am ET

CytoDyn Reports Preliminary Results from First Five Patients in Phase 2 NASH Open Label Leronlimab Trial. Lower Fatty Deposits in All 5 Patients by as Much as 45% and Lower Fibrosis in 4 Patients by a

Oct 28, 2021 11:08 am ET

CytoDyn Inc. Announces Adjournment of Annual Meeting of Shareholders to November 24, 2021 Due to Lack of Quorum

CytoDyn Inc. (OTCQB: CYDY) (the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today convened and then adjourned the 2021 Annual Meeting of Shareholders (the “Annual Meeting”) without transacting any other business. The Annual Meeting was adjourned to be held virtually on Wednesday, November 24, 2021 at 8:00 a.m. Pacific Time. The adjournment provides the Company with additional time to solicit proxies from its shareholders to achieve a quorum at the Annual Meeting.

Oct 28, 2021 12:41 am ET

CytoDyn Announces FDA Accepts Revised Rolling Review Timeline for Resubmission of its BLA

Oct 26, 2021 07:00 am ET

Two Virtual Investor Conferences the Small Cap Investor should not avoid.

EmergingGrowth.com a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth Companies and Markets announces the Schedule of the 19th Emerging Growth Conference. The Emerging...

Oct 25, 2021 06:00 am ET

CytoDyn Announces Treatment of First Patient in Pivotal Phase 3 Trial for Critically Ill COVID-19 Patients in Brazil

Oct 21, 2021 06:00 am ET

CytoDyn to Hold Webcast and Live Q/A on October 26

Oct 20, 2021 04:27 pm ET

CytoDyn Announces Delaware Court Has Denied Activist Group’s Motion to Prevent Annual Meeting from Taking Place

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the Delaware Court of Chancery has denied a motion by the activist group led by Paul Rosenbaum and Bruce Patterson (the “Activist Group”) to prevent the Company’s 2021 Annual Meeting of Stockholders (the “Annual Meeting”) from taking place as scheduled on October 28, 2021.

Oct 18, 2021 07:00 am ET

CytoDyn Alerts Shareholders to Vote on Company’s Proxy Card Ahead of October 28th Annual Meeting

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that shareholders will receive proxy material beginning this week from the Company in connection with its upcoming 2021 Annual Meeting of Stockholders on October 28, 2021 (the “Annual Meeting”).

Oct 14, 2021 11:38 am ET

Group of CytoDyn Stockholders Comments on Delaware Court Decision

A group of long-time stockholders (the “Investor Group”) of CytoDyn Inc. (“CYDY” or the “Company”) that has nominated five highly experienced director candidates to serve on the Company’s Board of Directors today commented on the decision made by the Delaware Court of Chancery to deny the Investor Group’s request to force the Company to allow stockholders the opportunity to vote for the Investor Group’s nominees.

Oct 14, 2021 07:00 am ET

Delaware Court Agrees with CytoDyn that Activist Group’s Nominations are Invalid

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that the Delaware Court of Chancery found that CytoDyn’s Board of Directors properly rejected a nomination notice presented by an activist group led by Paul Rosenbaum and Bruce Patterson (the “Rosenbaum/Patterson Group” or the “Activist Group”). All of the Activist Group’s claims were denied and judgment was entered for CytoDyn and its Board.

Oct 12, 2021 07:00 am ET

CEO Presenting on the Emerging Growth Conference on October 13 Register Now

EmergingGrowth.com, a leading independent small cap media portal with an extensive history of providing unparalleled content for the Emerging Growth Companies and Markets, announces the Schedule of the 18th Emerging Growth Conference. The Emerging...

Oct 07, 2021 02:27 pm ET

CytoDyn to Present at Emerging Growth Conference on October 13 Followed by Live Q/A

Oct 07, 2021 06:02 am ET

CytoDyn Announces Study to Evaluate Potential Synergistic Effects of Leronlimab with Immune Checkpoint Blockade (ICB)

Oct 07, 2021 06:01 am ET

CytoDyn Names Chris Recknor, M.D. Senior Executive VP of Clinical Operations to Initiate Two New Clinical Trials for Stroke and Alzheimer’s, While Nitya Ray, Ph.D. is Named CytoDyn’s New COO to Lead C

Oct 07, 2021 06:00 am ET

CytoDyn Announces Legal Actions Against its Former CRO, Amarex Clinical Research

Sep 29, 2021 12:57 pm ET

CytoDyn Comments on Rosenbaum/Patterson Activist Group “Plan”

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today responded to the “plan” put forward by an activist group led by Paul Rosenbaum and Bruce Patterson (the “Rosenbaum/Patterson Group” or the “Activist Group”):

Sep 29, 2021 08:00 am ET

CytoDyn Comments on Rosenbaum/Patterson Activist Group “Plan”

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today responded to the “plan” put forward by an activist group led by Paul Rosenbaum and Bruce Patterson (the “Rosenbaum/Patterson Group” or the “Activist Group”):

Sep 28, 2021 07:00 am ET

CEO Presenting on the Emerging Growth Conference on September 29 Register Now

Sep 27, 2021 06:30 pm ET

Group of CytoDyn Stockholders Releases White Paper Regarding Company’s Extremely Unfavorable Borrowing Practices

Sep 27, 2021 12:30 pm ET

CytoDyn to Present at Emerging Growth Conference on September 29 Followed by Live Q/A

CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer and Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development of CytoDyn will provide a comprehensive business update at the upcoming Emerging Growth Conference. CytoDyn will present for 20 minutes, and 40 minutes will be dedicated to live questions and answers.

Sep 24, 2021 08:00 am ET

Group of CytoDyn Stockholders Shares Strategic Plan to Obtain Cancer Therapy Approval for Leronlimab

A group of long-time stockholders (the “Nominating Stockholders” or the “Group”) of CytoDyn Inc. (“CYDY or the “Company”) (OTC: CYDY) that has nominated five highly experienced director candidates to serve on the Company’s Board of Directors today announced its comprehensive strategic plan to obtain cancer therapy approval for Leronlimab. If implemented, the Group believes this plan would begin to generate much-needed revenue for CYDY and position the Company to earn FDA approval for the drug, while enhancing the value of all stockholders’ shares.

Sep 22, 2021 08:00 am ET

CytoDyn Receives Clearance from Brazil’s FDA (ANVISA) to Commence a Pivotal Phase 3 Trial in Critically Ill COVID-19 Patients with IV Administration of Four Doses (700mg/week)

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that Brazil’s regulatory authority, ANVISA (Agência Nacional de Vigilância Sanitária), has approved the start of an additional Phase 3 CD16 clinical trial of leronlimab.

Sep 21, 2021 08:00 am ET

CytoDyn’s Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at the World Antiviral Congress 2021

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that Dr. Scott Kelly, CytoDyn’s Chairman of the Board, Chief Medical Officer and Head of Business Development, will be presenting at the World Antiviral Congress 2021. The Congress will be held from November 30 – December 2, 2021, in San Diego.

Sep 20, 2021 11:00 am ET

Group of CytoDyn Stockholders Announces Federal Court Dismisses Litigation Brought by Company

A group of long-time stockholders (the “Nominating Stockholders” or the “Group”) of CytoDyn Inc. (“CYDY or the “Company”) (OTC: CYDY) that has nominated five highly experienced director candidates to serve on the Company’s Board of Directors today announced that Judge Maryellen Noreika has approved a joint stipulation to dismiss CYDY’s lawsuit in the United States District Court for the District of Delaware. The litigation, which related to disclosures by the Nominating Stockholders, was an attempt by CYDY to prevent stockholders from having the opportunity to vote for the Nominating Stockhold

Sep 20, 2021 10:18 am ET

CytoDyn Announces Resolution of Federal Litigation with Rosenbaum/Patterson Activist Group

The Board of Directors (the “Board”) of CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the resolution of its lawsuit (the “Federal Lawsuit”) brought in the United States District Court for the District of Delaware against the activist group led by Paul Rosenbaum and Bruce Patterson (the “Rosenbaum/Patterson Group” or the “Activist Group”).

Sep 17, 2021 08:00 am ET

Bruce Patterson, M.D., Director Candidate for CytoDyn Board, Presents at International COVID Summit

A group of long-time stockholders (the “Nominating Stockholders”) of CytoDyn Inc. (“CYDY or the “Company”) (OTC: CYDY) that has nominated five highly experienced director candidates to serve on the Company’s Board of Directors today announced that Bruce Patterson, M.D., one of the candidates, attended and presented at the International COVID Summit, held in Rome, Italy from September 12-14, 2021.

Sep 15, 2021 10:18 am ET

Glancy Prongay & Murray LLP Announces Investigation of CytoDyn Inc.

Glancy Prongay & Murray LLP (“GPM”) announces its investigation of CytoDyn Inc. (OTCQB:CYDY) concerning the Company and its directors’ and officers’ possible violations of state laws.

Sep 14, 2021 07:00 am ET

CEO Presenting on the Emerging Growth Conference on September 15. Register Now

Sep 13, 2021 06:00 am ET

CytoDyn to Present at Emerging Growth Conference on September 15 Follow by Live Q/A

Sep 09, 2021 08:29 pm ET

CytoDyn Announces Treatment of the First Patient in its Pivotal Phase 3 COVID-19 Trial in Brazil for Patients with Severe Symptoms

Sep 07, 2021 08:30 am ET

Group of CytoDyn Stockolders Responds to Misleading Company News Release

A group of long-time stockholders (the “Nominating Stockholders”) of CytoDyn Inc. (“CYDY” or the “Company”) (OTC: CYDY) that has nominated five highly experienced director candidates to serve on the Company’s Board of Directors today responded to a news release issued by CYDY on September 3, 2021 that completely misrepresented a voluntary stipulation filed by the Nominating Stockholders in the litigation initiated by the Company in the United States District Court. This misrepresentation is a blatant attempt to quash shareholders’ ability to vote for an alternate slate of directors.

Sep 02, 2021 06:40 pm ET

CytoDyn to Hold Webcast on September 8 to Discuss Results from mTNBC Trials, HIV BLA Status, and Updates on COVID-19 and NASH Trials

CytoDyn Inc. (OTCQB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and...

Sep 02, 2021 05:32 pm ET

CytoDyn Highlights Court Ordering Rosenbaum/Patterson Group to Comply With the Federal Securities Laws

The Board of Directors (the “Board”) of CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today issued a statement to shareholders commenting on the Court Order entered yesterday by a United States District Court Judge in the lawsuit brought by CytoDyn against the activist group led by Paul Rosenbaum and Bruce Patterson (the “Rosenbaum/Patterson Group,” the “Activist Group”).

Sep 02, 2021 08:30 am ET

Group of CytoDyn Stockholders Warns Stockholders of Board’s Continued Value Destruction and Failures

A group of long-time stockholders (the “Group”) of CytoDyn Inc. (“CYDY” or the “Company”) (OTC: CYDY) that has nominated five highly experienced director candidates to serve on the Company’s Board of Directors today released a letter to fellow stockholders outlining recent ill-advised actions and announcements made by CYDY’s current leadership that have further destroyed the Company’s value and damaged its credibility.

Aug 26, 2021 05:02 pm ET

CytoDyn Appoints Seenu Srinivasan, Ph.D. as Executive Director of CMC Regulatory Affairs

Aug 26, 2021 08:30 am ET

Group of CytoDyn Stockholders Files Lawsuit to Force Company to Allow Stockholders to Vote for Alternative Director Nominees

A group of long-time stockholders (the “Group”) of CytoDyn Inc. (“CYDY or the “Company) (OTC: CYDY) that has nominated five highly experienced director candidates to serve on the Company’s Board of Directors today announced that it has filed a lawsuit in the Delaware Court of Chancery seeking to force CYDY to allow stockholders to vote for the Group’s nominees. CYDY has previously filed litigation seeking to block the ability of stockholders to vote for the Group’s nominees as an alternative to the current CYDY Board and has issued several communications falsely stating that stockholders canno

Aug 25, 2021 08:34 am ET

CytoDyn Urges Shareholders to Ignore Proxy Cards from Rosenbaum/Patterson Group

Aug 25, 2021 08:00 am ET

CytoDyn’s Final mTNBC Report Indicates as Much as 980% Increase in 12-Month Overall Survival and Up to 660% in 12-Month Modified Progression Free Survival

Aug 19, 2021 03:51 pm ET

Group of CytoDyn Stockholders Responds to Highly Misleading Company Release

A group of long-time stockholders (the “Nominating Stockholders”) of CytoDyn Inc. (“CYDY or the “Company) (OTC: CYDY) that has nominated five highly experienced director candidates to serve on the Company’s Board of Directors today issued the following statement in response to the highly misleading news release issued this morning by CYDY:

Aug 19, 2021 08:00 am ET

CytoDyn Provides Update on Rosenbaum/Patterson Group Litigation

The Board of Directors (the “Board”) of CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today issued the following statement regarding the continued efforts of an activist group led by Paul Rosenbaum and Bruce Patterson (the “Rosenbaum/Patterson Group” or the “Group”) to mislead shareholders and engage in an unlawful proxy contest to replace a majority of the Company’s Board.

Aug 13, 2021 06:00 am ET

CytoDyn Receives FDA Guidance for its HIV BLA Dose Justification Report

Aug 05, 2021 09:26 am ET

CytoDyn Files Lawsuit Against Rosenbaum/Patterson Activist Group for Misleading Shareholders and Waging an Unlawful Proxy Contest

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company, today announced that it has filed a lawsuit in the United States District Court for the District of Delaware against the activist group led by Paul Rosenbaum and Bruce Patterson (the “Rosenbaum/Patterson Group” or the “Activist Group”). The suit seeks to enjoin the Activist Group from misleading shareholders and waging an illegal proxy contest to take over control of the Company’s Board of Directors (the “Board”).

Aug 03, 2021 06:00 am ET

CytoDyn Receives Clearance from Brazil’s ANVISA to Commence Phase 3 Trial for Severe COVID-19 Patients

CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that Brazil’s regulatory authority ANVISA (Agência Nacional de Vigilância Sanitária) has approved the previously submitted clinical trial protocol to commence patient enrollment in its CD17 trial for severe COVID-19 patients. The Academic Research Organization (ARO) Albert Einstein Israelite Hospital (AEIH) in Brazil will conduct the trial.

Aug 02, 2021 07:00 am ET

CytoDyn Announces That Director Nominations by Rosenbaum/Patterson Activist Group Are Invalid

CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company, announced today that the director nominations submitted by an activist group led by Paul Rosenbaum and Bruce Patterson (the “Rosenbaum/Patterson Group”) were invalid. The Rosenbaum/Patterson Group attempted to nominate five director candidates to take over control of the Company’s six-member Board of Directors (the “Board”).

Jul 19, 2021 04:41 pm ET

CytoDyn to Hold Webcast on July 22 to Discuss Results from Cancer Trials, HIV BLA Status, NASH, and COVID-19 Trials

Jul 19, 2021 06:00 am ET

CytoDyn Announces Preliminary Results from 30 mTNBC Patients Treated with Leronlimab. Decreases in CAMLs after 4 Doses of Leronlimab were Identified in Over 70% of Patients and were Associated with a

Jul 12, 2021 06:00 am ET

CytoDyn’s Trial for Metastatic Triple-Negative Breast Cancer Demonstrates Safety with 350 mg, 525 mg and 700 mg Dosages; Officially Advances to Phase 2 from Phase 1b

Jul 06, 2021 06:00 am ET

CytoDyn Granted a Significant Patent by USPTO for Methods of Treating Coronavirus Infection with Leronlimab

CytoDyn Inc. (OTCQB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today its drug candidate, leronlimab, has been...

Jul 01, 2021 06:07 pm ET

CytoDyn Submits Dose Justification Report to FDA to Begin Overcoming Deficiencies in its BLA for HIV

Jul 01, 2021 05:32 pm ET

Group of Cytodyn Stockholders Nominates Five Highly Qualified Director Candidates to Replace Board Responsible for Mismanagement and Value Destruction

A group of long-time stockholders (the “Nominating Stockholders”) of CytoDyn Inc. (“CYDY or the “Company) (OTC: CYDY) today announced that it has sent a notice to CYDY nominating five highly experienced director candidates – Thomas Errico, MD, Bruce Patterson, MD, Paul Rosenbaum, Peter Staats, MD and Melissa Yaeger – to serve on the Company’s Board of Directors.

Jun 21, 2021 08:30 am ET

CytoDyn Inc. Announces Positive Preliminary Results of Unblinded Data from Long-Haulers Trial Showing Greater Improvement in Leronlimab Group over Placebo in 18 of 24 Symptoms

Jun 16, 2021 04:01 pm ET

CytoDyn to Hold Webcast on June 21 to Discuss Unblinded Data from COVID-19 Long-Haulers Trial and Other Developments

Jun 10, 2021 09:30 am ET

SHAREHOLDER ALERT: CytoDyn Inc. (CYDY) Officers and Directors Under Investigation for Possible False Statements and Insider Trading

SAN FRANCISCO, June 10, 2021 /PRNewswire/ -- Schubert Jonckheer & Kolbe LLP is investigating potential derivative claims on behalf of shareholders of CytoDyn Inc. (OTC: CYDY) relating to possible false statements to investors and insider trading by two officers and a director.

Jun 07, 2021 08:51 am ET

Nature Communications Publishes Study of CytoDyn’s Leronlimab Preventing HIV Infection in Primates

CytoDyn Inc. (OTC.QB: CYDY), ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the publication in Nature...

Jun 01, 2021 09:23 am ET

CytoDyn and Philippine Airlines Work Together to Provide Filipinos with the Best Possible Treatment Options In the Fight Against Covid-19

CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab), a CCR5 antagonist with potential multiple therapeutic indications, announced today a joint collaborative effort with...

Jun 01, 2021 09:15 am ET

CytoDyn Receives First Purchase Order from Chiral Pharma Corporation for Use of Leronlimab Under CSP for COVID-19 Patients in the Philippines

CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-Pro 140), a CCR5 antagonist with potential multiple therapeutic indications, announced today that Chiral Pharma...

May 27, 2021 06:00 am ET

Biomm S.A. Announces Plans to Submit Authorization to Conduct Phase 3 Clinical Studies of Leronlimab with ANVISA in Brazil in the Next Few Days

CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing Vyrologix™ (leronlimab-PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced that its Brazilian...

May 20, 2021 04:55 pm ET

Antonio Migliarese Promoted to Chief Financial Officer of CytoDyn

May 18, 2021 06:00 am ET

CytoDyn to Submit Newly Completed Topline Report of CD12 Trial Results to Regulatory Agencies in Multiple Countries including India and Philippines

May 17, 2021 07:44 pm ET

CytoDyn to Hold Webcast on May 18 to Discuss FDA’s Statement on Leronlimab

May 17, 2021 11:15 am ET

DEADLINE ALERT for NEPT, BLU, RIDE, and CYDY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....

May 16, 2021 05:15 pm ET

CYDY Final Deadline Tomorrow: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages CytoDyn Inc. Investors to Secure Counsel Before Important May 17 Deadline in Securities Class Action – CYDY

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of CytoDyn Inc. (OTC: CYDY) between March 27, 2020 and March 9, 2021, inclusive (the “Class Period”), of the important May 17, 2021 lead plaintiff...

May 14, 2021 10:30 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CytoDyn Inc. - CYDY

May 14, 2021 11:11 am ET

Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Filed Against CytoDyn Inc. – CYDY

The law firm of Kessler Topaz Meltzer & Check, LLP announces that a securities fraud class action lawsuit has been filed in the United States District Court for the Western District of Washington against CytoDyn Inc. (OTCMKTS: CYDY) (“CytoDyn”) on...

May 13, 2021 10:00 pm ET

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against CytoDyn, Inc. and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the Western District of Washington on behalf of investors that purchased CytoDyn, Inc. (Other OTC: CYDY) common stock between March 27, 2020 and March 9, 2021, inclusive (the “Class Period”). Investors have until May 17, 2021 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

May 13, 2021 12:45 pm ET

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against CytoDyn, Inc. (CYDY)

The Law Offices of Frank R. Cruz reminds investors of the upcoming May 17, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased CytoDyn, Inc. (“CytoDyn, Inc.” or the “Company”) (OTC:

May 13, 2021 11:00 am ET

DEADLINE ALERT for RIDE, CYDY, ROOT, VRM: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion....

May 13, 2021 08:56 am ET

CytoDyn Signs Distribution Agreement with Macleods Pharmaceuticals Ltd. to Pursue EUA and Compassionate Use Access to Leronlimab in India

CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (Vyrologix or PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today it has executed...

May 12, 2021 09:53 pm ET

SHAREHOLDER ALERT: CLAIMSFILER REMINDS CYDY, RIDE, ROOT, VRM INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits: Lordstown Motors Corp. (RIDE) Class Period: 8/3/2020 - 3/24/2021Lead Plaintiff Motion Deadline: May 17,...

May 12, 2021 11:00 am ET

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against CytoDyn, Inc. (CYDY)

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming May 17, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired CytoDyn, Inc. (“CytoDyn” or the...

May 12, 2021 09:00 am ET

Scott+Scott Attorneys at Law LLP Alerts Investors with Losses Over $250,000 to Securities Class Action Against CytoDyn, Inc. (CYDY)

Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, announces the filing of a class action lawsuit against CytoDyn, Inc. (“CytoDyn”) (OTCQB: CYDY) and certain of its officers, alleging...

May 11, 2021 10:34 pm ET

FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of CYDY, RIDE, ROOT and VRM

The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies. Lordstown Motors Corp. (RIDE) Class Period: August 20, 2020 and March 24, 2021Lead Plaintiff Motion Deadline:...

May 11, 2021 06:26 pm ET

CytoDyn, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm

The Portnoy Law Firm advises investors that a class action lawsuit has been filed on behalf of CytoDyn, Inc. (OTCQB: CYDY) investors that acquired shares between March 27, 2020 and March 9, 2021. Investors have until April 19, 2021 to seek an...

May 10, 2021 11:21 pm ET

SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS CYDY, RIDE, ROOT, VRM INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors of pending deadlines in the following securities class action lawsuits: Lordstown Motors Corp. (RIDE) Class Period:...

May 10, 2021 02:45 pm ET

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages CytoDyn Inc. Investors to Secure Counsel Before Important May 17 Deadline in Securities Class Action – CYDY

May 10, 2021 12:00 pm ET

DEADLINE ALERT for NEPT, BLU, RIDE, and CYDY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

May 10, 2021 10:00 am ET

CYDY Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds CytoDyn, Inc. Investors With Losses Exceeding $100K of Class Action and Lead Plaintiff Deadline: May 17, 2021

May 09, 2021 03:10 pm ET

CYDY DEADLINE: Kessler Topaz Meltzer & Check, LLP Reminds Investors of CytoDyn Inc. of Deadline in Securities Fraud Class Action Lawsuit

The law firm of Kessler Topaz Meltzer & Check, LLP reminds CytoDyn Inc. (OTCMKTS: CYDY) (“CytoDyn”) investors that a securities fraud class action lawsuit has been filed in the United States District Court for the Western District of Washington...

May 08, 2021 04:46 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CytoDyn Inc. - CYDY

May 07, 2021 10:34 pm ET

SHAREHOLDER ALERT: CLAIMSFILER REMINDS CYDY, RIDE, ROOT, VRM INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

May 07, 2021 01:54 pm ET

CytoDyn, Inc. Investors: Last Days to Participate Actively in the Class Action Lawsuit; Portnoy Law Firm

May 07, 2021 06:00 am ET

CytoDyn’s Leronlimab Featured on OneNews in Philippines on May 9

May 06, 2021 11:16 am ET

DEADLINE ALERT for RIDE, CYDY, ROOT, VRM: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

May 06, 2021 11:11 am ET

Class Action Lawsuit Deadline: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against CytoDyn Inc.

May 05, 2021 11:24 pm ET

SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS CYDY, RIDE, ROOT, VRM INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

May 05, 2021 10:01 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bellus Health, Neptune Wellness, Sequential Brands, and CytoDyn and Encourages Investors to Contact the

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Bellus Health, Inc. (NASDAQ: BLU), Neptune Wellness Solutions, Inc. (NASDAQ:...

May 05, 2021 11:52 am ET

CYDY DEADLINE: Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against CytoDyn, Inc. – CYDY

Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of CytoDyn Inc. (OTC: CYDY) between March 27, 2020 and March 9, 2021, inclusive (the “Class Period”). To join the class action, go to...

May 05, 2021 03:35 am ET

CytoDyn Reaches Agreement with Albert Einstein Israelite Hospital in Brazil to Conduct Two COVID-19 Trials - a Small Trial in Critically Ill and a Large Trial in Severe Populations

May 04, 2021 10:50 pm ET

FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of CYDY, RIDE, ROOT and VRM

May 04, 2021 11:00 am ET

DEADLINE ALERT for NEPT, BLU, RIDE, and CYDY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

May 03, 2021 11:05 pm ET

SHAREHOLDER ALERT: CLAIMSFILER REMINDS CYDY, RIDE, ROOT, VRM INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

May 03, 2021 12:00 pm ET

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against CytoDyn, Inc. (CYDY)

May 03, 2021 09:05 am ET

CytoDyn to Hold Webcast on May 5 to Provide Update on Multiple Initiatives

May 03, 2021 09:02 am ET

Data from 10 Patients with Stage Four Cancer Treated with Leronlimab for Nearly One Year Will Serve as Basis for Pre-Breakthrough Therapy Designation Meeting with FDA

May 03, 2021 09:00 am ET

CytoDyn HIV Indication Update: Leronlimab HIV Extension Arm Nearing 7 Years with Continued Excellent Safety Results

CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (Vyrologix™ or PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today a comprehensive...

May 02, 2021 03:31 pm ET

Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against CytoDyn Inc.

May 02, 2021 01:16 pm ET

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages CytoDyn Inc. Investors with Losses to Secure Counsel Before Important May 17 Deadline in Securities Class Action – CYDY

Apr 30, 2021 10:50 pm ET

SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS CYDY, RIDE, ROOT, VRM INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

Apr 28, 2021 10:50 pm ET

SHAREHOLDER ALERT: CLAIMSFILER REMINDS CYDY, RIDE, ROOT, VRM INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

Apr 28, 2021 09:19 pm ET

CytoDyn Inc. Class Action Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Shareholders of Deadline in Securities Fraud Class Action Lawsuit

Apr 28, 2021 03:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bellus Health, Neptune Wellness, Sequential Brands, and CytoDyn and Encourages Investors to Contact the

Apr 28, 2021 10:00 am ET

SQBG, CYDY & RIDE Shareholder Alerts: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Investors to Contact the Firm

Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...

Apr 27, 2021 11:00 pm ET

FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of CYDY, RIDE, ROOT and VRM

Apr 27, 2021 05:02 pm ET

ROSEN, SKILLED INVESTOR COUNSEL, Encourages CytoDyn Inc. Investors With Losses to Secure Counsel Before Important May 17 Deadline in Securities Class Action – CYDY

Apr 27, 2021 04:01 pm ET

CytoDyn’s Chief Medical Officer Dr. Scott Kelly to Present at Triple Negative Breast Cancer Drug Development Digital Summit 2021 on April 28

Apr 27, 2021 10:00 am ET

DEADLINE ALERT for NEPT, BLU, RIDE, and CYDY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Apr 26, 2021 10:42 pm ET

SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS CYDY, RIDE, ROOT, VRM INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

Apr 24, 2021 08:38 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CytoDyn Inc. - CYDY

Apr 24, 2021 03:21 pm ET

Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Filed Against CytoDyn Inc.

Apr 23, 2021 10:50 pm ET

SHAREHOLDER ALERT: CLAIMSFILER REMINDS CYDY, RIDE, ROOT, VRM INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

Apr 23, 2021 09:08 pm ET

ROSEN, A LEADING LAW FIRM, Encourages CytoDyn Inc. Investors With Losses to Secure Counsel Before Important May 17 Deadline in Securities Class Action – CYDY

Apr 23, 2021 03:00 pm ET

DEADLINE ALERT for RIDE, CYDY, ROOT, VRM: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Apr 22, 2021 11:52 pm ET

CytoDyn Completes $28.5 Million Convertible Note Financing with Conversion Rate at $10.00 Per Share Without Warrants

Apr 21, 2021 10:51 pm ET

SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS CYDY, RIDE, ROOT, VRM INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

Apr 21, 2021 06:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CytoDyn, Lordstown Motors, Root, and Vroom and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of CytoDyn, Inc. (Other OTC: CYDY), Lordstown Motors Corp. (NASDAQ: RIDE), Root,...

Apr 21, 2021 03:03 pm ET

CYDY ALERT: Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against CytoDyn, Inc. – CYDY

Apr 21, 2021 11:00 am ET

DEADLINE ALERT for NEPT, BLU, RIDE, and CYDY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Apr 21, 2021 09:00 am ET

Scott+Scott Attorneys at Law LLP Alerts Investors with Losses Over $250,000 to Securities Class Action Against CytoDyn, Inc. (CYDY)

Apr 20, 2021 10:56 pm ET

FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of CYDY, RIDE, ROOT and VRM

Apr 20, 2021 08:10 pm ET

Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against CytoDyn Inc. (CYDY)

Apr 19, 2021 11:00 pm ET

SHAREHOLDER ALERT: CLAIMSFILER REMINDS CYDY, RIDE, ROOT, VRM INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

Apr 19, 2021 06:05 am ET

CytoDyn Submits First and Most Crucial Section (CMC) of Interim Order Application to Health Canada for COVID-19 Under Rolling Review

CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with potential multiple therapeutic indications, announced today it has submitted the manufacturing...

Apr 19, 2021 06:00 am ET

Former President of the Philippines, Joseph Estrada, Among the Many COVID-19 Patients Receiving Leronlimab Under CSP in the Philippines

CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company"), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with potential multiple therapeutic indications, announced today former President of the Philippines,...

Apr 17, 2021 12:15 pm ET

CYDY INVESTOR NOTICE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages CytoDyn Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action

Apr 16, 2021 10:50 pm ET

SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS CYDY, RIDE, ROOT, VRM INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

Apr 16, 2021 04:04 pm ET

CYDY CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Reminds CytoDyn Inc. Shareholders of Securities Fraud Class Action Lawsuit

Apr 15, 2021 11:00 am ET

DEADLINE ALERT for NEPT, BLU, RIDE, and CYDY: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Apr 15, 2021 09:26 am ET

CytoDyn Executes Exclusive Supply and Distribution Agreement with Chiral Pharma Corporation to Provide Up to 200,000 vials of Leronlimab to Philippines

Apr 14, 2021 11:52 pm ET

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CytoDyn Inc. - CYDY

Apr 14, 2021 10:55 pm ET

SHAREHOLDER ALERT: CLAIMSFILER REMINDS CYDY, RIDE, ROOT, VRM INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

Apr 14, 2021 06:00 pm ET

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bellus Health, Neptune Wellness, Sequential Brands, and CytoDyn and Encourages Investors to Contact the

Apr 14, 2021 11:00 am ET

DEADLINE ALERT for RIDE, CYDY, ROOT, VRM: Law Offices of Howard G. Smith Reminds Investors of Class Actions on Behalf of Shareholders

Apr 13, 2021 11:00 pm ET

FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of CYDY, RIDE, ROOT and VRM

Apr 13, 2021 11:00 am ET

CYDY Investor Alert: Bronstein, Gewirtz & Grossman, LLC Reminds CytoDyn, Inc. Investors With Losses Exceeding $100K of Class Action and Encourages Shareholders to Contact the Firm

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against CytoDyn, Inc. ("CytoDyn” or "the Company") (OTCMKT: CYDY) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired CytoDyn securities between March 27, 2020 and March 9, 2021, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm’s site:

Apr 13, 2021 08:46 am ET

SHAREHOLDER ALERT: Lowey Dannenberg, P.C., Investigates Claims on Behalf of Investors of CytoDyn Inc. and Encourages Investors Who Lost More than $300,000 to Contact the Firm

Lowey Dannenberg P.C., a preeminent law firm in obtaining redress for consumers and investors, is investigating claims of violations of federal securities laws on behalf of investors of CytoDyn Inc. (“CytoDyn” or the “Company”) (OTCMKTS: CYDY). If...

Apr 12, 2021 10:57 pm ET

SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS CYDY, RIDE, ROOT, VRM INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

Apr 12, 2021 06:32 pm ET

Shareholder Alert: Robbins LLP Announces that CytoDyn Inc. (CYDY) is Being Sued for Misleading Shareholders

Shareholder rights law firm Robbins LLP announces that a purchaser of CytoDyn Inc. (OTC: CYDY) filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities Exchange Act of 1934 between March 27, 2020 and March 9, 2021.

Apr 12, 2021 11:27 am ET